DiaCarta Reports Positive Clinical Trial Data for Its Blood Based Test To Triage FIT-Positive Patients Enrolled in CRC Screening Programs

UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostic company, has announced the publication of its prospective clinical trial data on its blood-based test for triaging FIT (fecal immunochemical test)-positive patients in colorectal cancer (CRC) screening. The findings reveal that in triaging FIT-positive patients in CRC screening, the QuantiDNA™ test from patients’ plasma reduces the need for colonoscopy examinations by 33% and is non-inferior to the standard of care in detecting significant colorectal lesions.